28

P a

t i

e n

t

c a

r e

KeY Figures

1 SPECT-CT, 1 SPECT, 1 PET-CT camera, 1 dedicated breast gamma camera

8,000 diagnostic examinations/year (4,400 PET)

> 120 patients treated/year

NUCLEAR MEDICINE

Missions Providing high quality diagnostic and therapeutic services

using radioactive elements

Carrying out translational and early clinical research, with a particular focus on molecular imaging and new targeted radionuclide treatments

Delivering high quality pre- and postgraduate teaching in nuclear oncology

Integrating imaging into the multidisciplinary oriented approach to patient care

DePartMental organisation

The medical team comprises 5 nuclear medicine physicians, 1 radiopharmacist, 2 radiophysicists, 1 bio-imaging engineer, 7 imaging technologists and/or nurses, 2 clinical research assistants and 2 administrative assistants. The Institute’s PET-CT centre is also the referral unit for the Brussels public hospital network.

aPPlieD research sentinel node scintigraphy In sentinel node scintigraphy, a radioactive dye is injected that is then transported to the lymph nodes closest to the tumour. The accumulated radioactivity makes it possible to identify the sentinel lymph node during surgery using a hand-held detection probe. Analysis of this lymph node shows whether cancer cells have been released out of the tumour or not. Surgical and medical treatments can be adapted accordingly. This technique is mainly applied in breast cancer, but also in head and neck, prostate and gynaecological cancers.

early metabolic assessment of the efficacy of treatment Cancer cells often use more glucose than normal cells. PET imaging can show a reduction of the glucose used by the tumour at the beginning of treatment, which tends to be interpreted as a sign of treatment efficacy. Similarly, PET is used in drug development to provide an early indication of a new drug’s effectiveness.

radiolabelled antibodies for Pet-ct-based molecular imaging and dosimetry for radio-immunotherapy Monoclonal antibodies can be labelled with long-living positron emitting isotopes (e.g., Zr 89 labelled trastuzumab). When whole body PET-CT imaging is performed at multiple time points, the biodistribution and the biokinetics of the administered antibody can be measured. These quantitative data can be then used to predict the treatment efficacy of the cold antibody (e.g., trasuzumab in metastatic breast can- cer), or determine the optimal dosages of treatment for individual patients (e.g., Y90-labelled rituximab therapy for lymphoma patients).

Yttrium-90 labelled microspheres for the treatment of liver cancer This technique uses millions of tiny resin beads (microspheres) containing Yttrium-90 that are injected selectively in the artery leading to the liver tumour. The beads become fixed in the blood vessels and irradiate the tumour cells from within, using doses that are impossible using conventional radiotherapy.

Dirk Staelens Nuclear Medicine Technologist

Prof Patrick Flamen Nuclear Medicine Physician, Head of Department

Dr Kristoff Muylle Nuclear Medicine Physician

Dr Camillo Garcia Nuclear Medicine Physician

Bruno Vanderlinden Radiation Medicine Physicist